Publications:203
Gerard M Turino, MD
About Me
Dr. Turino came to St. Luke’s Roosevelt in 1983 as the first chairman of the newly merged St. Luke’s Roosevelt Hospital Department of Medicine from Columbia University College of Physicians & Surgeons where he was a Professor of Medicine. After his chairmanship he became the Founding Director of the James P. Mara Center for Lung Disease at St. Luke’s Roosevelt Hospital. The center has focused on lung matrix structure and cellular enzyme injury in chronic obstructive pulmonary disease (COPD) including alpha-1 antitrypsin deficiency (AATD) emphysema. Studies have evolved to develop a useful biomarker for COPD and a potential therapy which is under clinical trial.
He has served as president of the New York Heart Association, the American Thoracic Society and as founding chairman of the COPD Foundation. He was a J. Burns Amberson Lecturer and received the Edward Livingston Trudeau Medal for Research, Teaching and Clinical Care from the American Thoracic Society. Throughout his career he has served as a consultant to the National Heart, Lung and Blood Institute.
He has served as president of the New York Heart Association, the American Thoracic Society and as founding chairman of the COPD Foundation. He was a J. Burns Amberson Lecturer and received the Edward Livingston Trudeau Medal for Research, Teaching and Clinical Care from the American Thoracic Society. Throughout his career he has served as a consultant to the National Heart, Lung and Blood Institute.
Language
Position
About Me
Dr. Turino came to St. Luke’s Roosevelt in 1983 as the first chairman of the newly merged St. Luke’s Roosevelt Hospital Department of Medicine from Columbia University College of Physicians & Surgeons where he was a Professor of Medicine. After his chairmanship he became the Founding Director of the James P. Mara Center for Lung Disease at St. Luke’s Roosevelt Hospital. The center has focused on lung matrix structure and cellular enzyme injury in chronic obstructive pulmonary disease (COPD) including alpha-1 antitrypsin deficiency (AATD) emphysema. Studies have evolved to develop a useful biomarker for COPD and a potential therapy which is under clinical trial.
He has served as president of the New York Heart Association, the American Thoracic Society and as founding chairman of the COPD Foundation. He was a J. Burns Amberson Lecturer and received the Edward Livingston Trudeau Medal for Research, Teaching and Clinical Care from the American Thoracic Society. Throughout his career he has served as a consultant to the National Heart, Lung and Blood Institute.
He has served as president of the New York Heart Association, the American Thoracic Society and as founding chairman of the COPD Foundation. He was a J. Burns Amberson Lecturer and received the Edward Livingston Trudeau Medal for Research, Teaching and Clinical Care from the American Thoracic Society. Throughout his career he has served as a consultant to the National Heart, Lung and Blood Institute.